Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 7 de 7
Filtrar
Mais filtros










Base de dados
Intervalo de ano de publicação
1.
Biotechnol Lett ; 44(1): 45-57, 2022 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-34837582

RESUMO

After its emergence in late 2019 SARS-CoV-2 was declared a pandemic by the World Health Organization on 11 March 2020 and has claimed more than 2.8 million lives. There has been a massive global effort to develop vaccines against SARS-CoV-2 and the rapid and low cost production of large quantities of vaccine is urgently needed to ensure adequate supply to both developed and developing countries. Virus-like particles (VLPs) are composed of viral antigens that self-assemble into structures that mimic the structure of native viruses but lack the viral genome. Thus they are not only a safer alternative to attenuated or inactivated vaccines but are also able to induce potent cellular and humoral immune responses and can be manufactured recombinantly in expression systems that do not require viral replication. VLPs have successfully been produced in bacteria, yeast, insect and mammalian cell cultures, each production platform with its own advantages and limitations. Plants offer a number of advantages in one production platform, including proper eukaryotic protein modification and assembly, increased safety, low cost, high scalability as well as rapid production speed, a critical factor needed to control outbreaks of potential pandemics. Plant-based VLP-based viral vaccines currently in clinical trials include, amongst others, Hepatitis B virus, Influenza virus and SARS-CoV-2 vaccines. Here we discuss the importance of plants as a next generation expression system for the fast, scalable and low cost production of VLP-based vaccines.


Assuntos
Vacinas contra COVID-19/biossíntese , Plantas Geneticamente Modificadas/metabolismo , SARS-CoV-2/imunologia , Vacinas de Partículas Semelhantes a Vírus/biossíntese , Antígenos Virais/genética , Antígenos Virais/metabolismo , Vacinas contra COVID-19/economia , Vacinas contra COVID-19/genética , Expressão Gênica , Plantas Geneticamente Modificadas/genética , Proteínas Recombinantes/genética , Proteínas Recombinantes/metabolismo , Vacinas de Partículas Semelhantes a Vírus/economia , Vacinas de Partículas Semelhantes a Vírus/genética , Vacinas Virais/biossíntese , Vacinas Virais/genética
2.
Vaccine ; 36(22): 3064-3071, 2018 05 24.
Artigo em Inglês | MEDLINE | ID: mdl-27894719

RESUMO

Highly pathogenic avian influenza (HPAI) viruses cause a severe and lethal infection in domestic birds. The increasing number of HPAI outbreaks has demonstrated the lack of capabilities to control the rapid spread of avian influenza. Poultry vaccination has been shown to not only reduce the virus spread in animals but also reduce the virus transmission to humans, preventing potential pandemic development. However, existing vaccine technologies cannot respond to a new virus outbreak rapidly and at a cost and scale that is commercially viable for poultry vaccination. Here, we developed modular capsomere, subunits of virus-like particle, as a low-cost poultry influenza vaccine. Modified murine polyomavirus (MuPyV) VP1 capsomere was used to present structural-based influenza Hemagglutinin (HA1) antigen. Six constructs of modular capsomeres presenting three truncated versions of HA1 and two constructs of modular capsomeres presenting non-modified HA1 have been generated. These modular capsomeres were successfully produced in stable forms using Escherichia coli, without the need for protein refolding. Based on ELISA, this adjuvanted modular capsomere (CaptHA1-3C) induced strong antibody response (almost 105endpoint titre) when administered into chickens, similar to titres obtained in the group administered with insect cell-based HA1 proteins. Chickens that received adjuvanted CaptHA1-3C followed by challenge with HPAI virus were fully protected. The results presented here indicate that this platform for bacterially-produced modular capsomere could potentially translate into a rapid-response and low-cost vaccine manufacturing technology suitable for poultry vaccination.


Assuntos
Glicoproteínas de Hemaglutininação de Vírus da Influenza/imunologia , Vacinas contra Influenza/imunologia , Influenza Aviária/prevenção & controle , Vacinas de Partículas Semelhantes a Vírus/imunologia , Adjuvantes Imunológicos/administração & dosagem , Animais , Anticorpos Antivirais/sangue , Apresentação de Antígeno , Galinhas/imunologia , Glicoproteínas de Hemaglutininação de Vírus da Influenza/genética , Humanos , Vacinas contra Influenza/economia , Vacinas contra Influenza/genética , Polyomavirus , Aves Domésticas , Vacinação , Vacinas de Partículas Semelhantes a Vírus/economia , Vacinas de Partículas Semelhantes a Vírus/genética
3.
Vaccine ; 35(35 Pt A): 4480-4485, 2017 08 16.
Artigo em Inglês | MEDLINE | ID: mdl-28347504

RESUMO

Improved understanding of antigenic components and their interaction with the immune system, as supported by computational tools, permits a sophisticated approach to modern vaccine design. Vaccine platforms provide an effective tool by which strategically designed peptide and protein antigens are modularized to enhance their immunogenicity. These modular vaccine platforms can overcome issues faced by traditional vaccine manufacturing and have the potential to generate safe vaccines, rapidly and at a low cost. This review introduces two promising platforms based on virus-like particle and liposome, and discusses the methodologies and challenges.


Assuntos
Desenho de Fármacos , Tecnologia Farmacêutica/economia , Tecnologia Farmacêutica/normas , Vacinas de Partículas Semelhantes a Vírus/economia , Vacinas de Partículas Semelhantes a Vírus/normas , Antígenos , Humanos , Imunogenicidade da Vacina , Lipossomos , Vacinas de Partículas Semelhantes a Vírus/administração & dosagem , Proteínas Virais
4.
Biotechnol J ; 10(5): 715-27, 2015 May.
Artigo em Inglês | MEDLINE | ID: mdl-25880158

RESUMO

In recent years, the development of novel recombinant virus-like particles (VLPs) has been generating new perspectives for the prevention of untreated and arising infectious diseases. However, cost-reduction and acceleration of manufacturing processes for VLP-based vaccines or vectors are key challenges for the global health system. In particular, the design of rapid and cost-efficient purification processes is a critical bottleneck. In this review, we describe and evaluate new concepts, development strategies and unit operations for the downstream processing of VLPs. A special focus is placed on purity requirements and current trends, as well as chances and limitations of novel technologies. The discussed methods and case studies demonstrate the advances and remaining challenges in both rational process development and purification tools for large biomolecules. The potential of a new era of VLP-based products is highlighted by the progress of various VLPs in clinical phases.


Assuntos
Proteínas Recombinantes/isolamento & purificação , Tecnologia Farmacêutica/métodos , Vacinas de Partículas Semelhantes a Vírus/isolamento & purificação , Vetores Genéticos , Humanos , Proteínas Recombinantes/imunologia , Tecnologia Farmacêutica/tendências , Vacinas de Partículas Semelhantes a Vírus/biossíntese , Vacinas de Partículas Semelhantes a Vírus/economia
5.
Curr Pharm Des ; 19(31): 5564-73, 2013.
Artigo em Inglês | MEDLINE | ID: mdl-23394559

RESUMO

Advances in transient expression technologies have allowed the production of milligram quantities of proteins within a matter of days using only small amounts (tens of grams) of plant tissue. Among the proteins that have been produced using this approach are the structural proteins of viruses which are capable of forming virus-like particles (VLPs). As such particulate structures are potent stimulators of the immune system, they are excellent vaccine candidates both in their own right and as carriers of additional immunogenic sequences. VLPs of varying complexity derived from a variety of animal viruses have been successfully transiently expressed in plants and their immunological properties assessed. Generally, the plant-produced VLPs were found to have the expected antigenicity and immunogenicity. In several cases, including an M2e-based influenza vaccine candidate, the plant-expressed VLPs have been shown to be capable of stimulating protective immunity. These findings raise the prospect that low-cost plant-produced vaccines could be developed for both veterinary and human use.


Assuntos
Proteínas de Plantas/metabolismo , Vacinas de Partículas Semelhantes a Vírus/biossíntese , Proteínas Virais/metabolismo , Animais , Antígenos Virais/imunologia , Reatores Biológicos , Humanos , Fatores de Tempo , Vacinas de Partículas Semelhantes a Vírus/economia , Vacinas de Partículas Semelhantes a Vírus/imunologia , Vacinas Virais/economia , Vacinas Virais/imunologia
6.
Vaccine ; 31(15): 1950-5, 2013 Apr 08.
Artigo em Inglês | MEDLINE | ID: mdl-23422147

RESUMO

Group A streptococcus (GAS) causes a wide range of diseases, some of them related to autoimmune diseases triggered by repeated GAS infections. Despite the fact that GAS primarily colonizes the mucosal epithelium of the pharynx, the main mechanism of action of most vaccine candidates is based on development of systemic antibodies that do not cross-react with host tissues, neglecting the induction of mucosal immunity that could potentially block disease transmission. Peptide antigens from GAS M-surface protein can confer protection against infection; however, translation of such peptides into immunogenic mucosal vaccines that can be easily manufactured remains a challenge. In this work, a modular murine polyomavirus (MuPyV) virus-like particle (VLP) was engineered to display a GAS antigenic peptide, J8i. Heterologous modules containing one or two J8i antigen elements were integrated with the MuPyV VLP, and produced using microbial protein expression, standard purification techniques and in vitro VLP assembly. Both modular VLPs, when delivered intranasally to outbred mice without adjuvant, induced significant titers of J8i-specific IgG and IgA antibodies, indicating significant systemic and mucosal responses, respectively. GAS colonization in the throats of mice challenged intranasally was reduced in these immunized mice, and protection against lethal challenge was observed. This study shows that modular MuPyV VLPs prepared using microbial synthesis have potential to facilitate cost-effective vaccine delivery to remote communities through the use of mucosal immunization.


Assuntos
Vacinas Bacterianas/imunologia , Imunidade nas Mucosas/imunologia , Polyomavirus/genética , Streptococcus pyogenes/classificação , Streptococcus pyogenes/imunologia , Vacinação , Vacinas de Partículas Semelhantes a Vírus/imunologia , Administração Intranasal , Animais , Formação de Anticorpos/imunologia , Antígenos de Bactérias/imunologia , Vacinas Bacterianas/economia , Vacinas Bacterianas/genética , Feminino , Camundongos , Infecções Estreptocócicas/imunologia , Infecções Estreptocócicas/prevenção & controle , Vacinas de Partículas Semelhantes a Vírus/economia , Vacinas de Partículas Semelhantes a Vírus/genética
7.
Hum Vaccin Immunother ; 9(1): 26-49, 2013 Jan.
Artigo em Inglês | MEDLINE | ID: mdl-22995837

RESUMO

Virus-like particles (VLPs) are self-assembled structures derived from viral antigens that mimic the native architecture of viruses but lack the viral genome. VLPs have emerged as a premier vaccine platform due to their advantages in safety, immunogenicity, and manufacturing. The particulate nature and high-density presentation of viral structure proteins on their surface also render VLPs as attractive carriers for displaying foreign epitopes. Consequently, several VLP-based vaccines have been licensed for human use and achieved significant clinical and economical success. The major challenge, however, is to develop novel production platforms that can deliver VLP-based vaccines while significantly reducing production times and costs. Therefore, this review focuses on the essential role of plants as a novel, speedy and economical production platform for VLP-based vaccines. The advantages of plant expression systems are discussed in light of their distinctive posttranslational modifications, cost-effectiveness, production speed, and scalability. Recent achievements in the expression and assembly of VLPs and their chimeric derivatives in plant systems as well as their immunogenicity in animal models are presented. Results of human clinical trials demonstrating the safety and efficacy of plant-derived VLPs are also detailed. Moreover, the promising implications of the recent creation of "humanized" glycosylation plant lines as well as the very recent approval of the first plant-made biologics by the U. S. Food and Drug Administration (FDA) for plant production and commercialization of VLP-based vaccines are discussed. It is speculated that the combined potential of plant expression systems and VLP technology will lead to the emergence of successful vaccines and novel applications of VLPs in the near future.


Assuntos
Biotecnologia/métodos , Plantas Geneticamente Modificadas , Tecnologia Farmacêutica/métodos , Vacinas de Partículas Semelhantes a Vírus/imunologia , Vacinas de Partículas Semelhantes a Vírus/isolamento & purificação , Animais , Biotecnologia/economia , Ensaios Clínicos como Assunto , Humanos , Modelos Animais , Tecnologia Farmacêutica/economia , Fatores de Tempo , Vacinas de Partículas Semelhantes a Vírus/economia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...